Olokizumab
Olokizumab
Olokizumab (pronounced: oh-loh-ki-zoo-mab) is a monoclonal antibody designed for the treatment of rheumatoid arthritis and other autoimmune diseases. It is developed by R-Pharm and is currently in the late stages of clinical trials.
Etymology
The name "Olokizumab" follows the World Health Organization's guidelines for the International Nonproprietary Names of monoclonal antibodies. The prefix "Olo-" is randomly assigned, the infix "-kizu-" indicates that the drug targets the interleukin system, and the suffix "-mab" denotes that it is a monoclonal antibody.
Mechanism of Action
Olokizumab works by binding to interleukin-6 (IL-6), a protein that plays a key role in the inflammatory response of the immune system. By blocking the action of IL-6, Olokizumab can help to reduce inflammation and slow the progression of autoimmune diseases.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
- Autoimmune diseases: A condition arising from an abnormal immune response to a normal body part.
- Interleukin-6: A cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases.
External links
- Medical encyclopedia article on Olokizumab
- Wikipedia's article - Olokizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski